Dr. Paul Karila appointed Head of Discovery Services at Cellectricon AB
News Jun 13, 2012
Cellectricon is pleased to announce the appointment of Paul Karila as the company’s Head of Discovery Services. Dr. Karila brings a solid and highly impressive neuroscience discovery track record to Cellectricon, important for the company’s expansion in bringing state-of-the-art discovery services to market. Paul has extensive experience of the drug discovery industry and has held several management positions at AstraZeneca.
The Company’s Discovery Services will be based on the proprietary Cellaxess® Elektra platform for automated cellular electric field manipulation enabling novel screening applications in the CNS and Cardiovascular therapeutic fields.
Cellectricon’s CEO David Burns said: “Cellectricon is delighted with the appointment of Dr. Karila. We are looking forward to working with Paul’s experience and direction to broaden our cell-based CNS and Cardiovascular Discovery Services using the Company’s strong IP and technology position to accelerate discovery through collaborations with our pharmaceutical partners”.
Dr. Karila added: “Cellectricon has a strong reputation in the discovery industry with equally strong customer validation and well-earned reputation for providing groundbreaking products and services to the pharmaceutical and life science research markets. Working with the strong scientific team, I will focus on further developing and providing outstanding cell-based discovery services to our customers to accelerate their drug discovery and biological research. “
Cellectricon is a leading provider of advanced cell-based screening technologies and services to accelerate drug discovery and cell-based assay research. Our proprietary technologies include leading systems for high resolution ion-channel screening and cell engineering. Developed in close collaboration with leaders in the pharmaceutical industry and esteemed research labs, the Cellaxess® Technology enables scalable field stimulation, compound delivery and transfection for genomic screening of primary cells, neurones and stem cells. The Dynaflow® Technology advances ion channel research and discovery applications.
Key Cancer-Linked Proteins Thought to be ‘Undruggable’ Until NowNews
A new study published in Nature, conducted by an alliance between industry and academia involving the University of Liverpool, highlights a new approach to targeting key cancer-linked proteins, thought to be ‘undruggable’.READ MORE
Researchers Reveal How Superbug Secretes It’s ToxinNews
Monash University’s Biomedicine Discovery Institute (BDI) researchers have created the first high-resolution structure depicting a crucial part of the ‘superbug’ Pseudomonas aeruginosa. The image identifies the ‘nanomachine’ used by the highly virulent bacteria to secrete toxins, pointing the way for drug design targeting this.READ MORE